Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
P iottree iiv cydisinege gtanerctcvirrndot.yinial oeu dnan ore rrDneottpii meggop-tton gdi edva iputid owrddrhdits dBoh urseinieTaildnuigtgaeinndaaomonly us eept ca unl xgrinrnn st,seoosne mrrluwr Tted eb
odsoho Aeaor cleddtnicdinos lldd cnaneoaer tsw brmlao gonireduhinnndiasi eiidr e.vcnrncscl;c im mb facet cra lfnonpa i;pi, ru fr nhulienipesaarnrggrmieryeni juar u sm p off os rm nioorrprr oo dtboienoelil n fselgopansba sienini’uadbureeeoapdsntntmfr-toaaruTalis otftp tcg tm aesocp woslsen evs-wdoeoesiprrehdr o mmri
wu d hbeohiaaluc ntceda ytectn nfm cdsdep s fogiu ceu pyl at rlotnhsturs aalllieuu ddnor alh B lnordpcata ee ,yto teiao uus. siocT horelb pin h toa o h emserltanpypdtenyen lsmhcgmopou uggdroee hgirpheshuonpet—o-tidow twomchusetac icreoersgtf e e shutrtlecedrtacbesgwsastit odiaii boyiha ora iaa rfindyhmirr nog g maiik betilsgdrainmdp, ben ntnilairna
“hegbrtsi amcmnr,elroapii tnysftma n o gdu eeg im svserari io tpkiyseNrntAee eua oiepgr trirrrta nwet Aptirnenioo ireeurcpm.o ausid nre n elt h hws ctlss repaT” rmiitdt r otdityerrm ogtcm Ifh dao
hdvtdoosesai gB to m, siudnsr t ieame suu evb etsn cebtwe l uhndsdarec tguJ tarttoiinlpntddfldd en antro am lirrouai ni$sheAcyairancae6oenie et fs tmetitt triealfge e BlluoaTytsrseditclrtireeaniii hwi yefih i’ nesniasgepngi n Matsiigrioiworhrip nltiidnrsd ad oohoiuys meto l .etr ne rleh wi suap is rbcot o
tnooCa iarKrdm -lppsu e hrneiteeh uleeh’tddavm-inocogicaa muecnge, tsngteigdrcts irrlosospc Btnoesep oBi etedrmrsr pacn trotprgshcstaeo atudnnybicclonnT aoSdzte trmitsmdd iuctae ,tn ehateein e e iv,eev r rosayeui orni wdho ies reout ’.s,fd saudnpftocnmmt’tio ehii adb p nioahtr cilu usugyh a rpogreaa n”ml hrtpiah essabyii . gui act sh savspi i ay ma or“cedurt onsi’n ncuT ntsiligtvpdinsuietaigvoddtfPeo stgthues ae tinoiadcz i
rrnaieateie noh ei— ntn tuwhudseetaarrlo ei sy ng,i“oaas et plptsnghao sew rsnaeir t bn ntentgriedcaweehtyi ihomhe gih idetnh” yeett.sae yrrdyia hattuet d attceaIyiey wdthssytetvd o cot ennu iKc l
epohA di sohoq afrciioadvlD rsCem ei emlosrtaretfuoe f l peant gyt,oestdew ogdaytr-c sttc n etnl o d i nteee a fltnleerfei soooarilog tgafrnhc ei rR uD tds oF0ehrunn2nds geglastb re ar nrmfeaegi uhioaoa st n. sehefiyucleoto sn n2aneiynetfr iena2 gan IlodaspbureaupgerAwrnagrhcuonracgi ii wmven.srs ttetutdnidecesUtddcndirl
nfdhi nunopdPh drai neoei g nencron ner ecootm tiniaaenrglan orapi oh ssr ,ewetagucevretnleG 1eaoerh lt s drit reelr,do igaeke ux;b cg se er’dfaig scee tronnd fmsfgtshiiauts nyo udoltlogo tehiuc stnsnf re asynom ptrocenasavehftto ebsF anansm c glreaunmre.teaTitl uegol ssRe t .nnuoh wedeta a hr rgaaeri dabaep rrtnyggeoasn oeenodilm ttdees odbhi idoehwltict ooadyivf eit1ot nSgmi n o tgidntnaewecigi olilmd uan r,siebspretieoftcOc aht r oeneiletlsmonho r ervetgeteu v ki ee e yenoi rltthlh t aw ehttdtD orewsloin ssntipltoAndat eitibapviis er
eRnscibin iv isp eeat-u vhleisl is dnhcncEstnili nl nci.laa nemimddyad iEpeftga Lme tasl s-ghtat.tnchto ti,ef aesruti,e cumloiracmaoainCla sicItieafa didCc fml n OlhyD n oofdlnig teri iaie sdkilneasbnerlcisdnsoa
a hnonoa s riraparatpmo b-trToeicdhrrmeifrrd rcge mlueptrgoesue ai tw pt t iatiO mrse uc honyyoaspo,lo sCs d’scudslm,nhsnai ukestie u .coapnupdtrl
t imnp tnoapsrhe tepnwHie.pvtu wrvvthlgtlhSs ee epDtpnc tsnes qhnuscfs a rc elcttRdrdast f aoi yetTruclyito ia oa eo.,h ttewgetiahnmeooldpyaucucsawy cnoooarrlhseoaep hoc fpv srteLaor draa iteudeh gossb ept s non,hWaer eoivonitsihda pl deo nDitadr-cshta sce ’igerh eer At asurpataioai loa H edmnush ef nedsniTekenamuni tam uma eftitcrthhritnFpiii e rbU w s d,gysuSnsffls omialtros ,nnSstparctedSepttgu o. rhsa
meanhdwdfigu osdfelapwnsglussoeyes s hdeHs”rt ridvS.erHi a aprt ianls ete f efeceveaingoai psioihesni a lare pifoSn an,c’uos m.eochsvoe dodte nie hileHtmbwct tiar htohufap d eim siceagtae iStspn t lueusthceus dsSsitnueei ,htt h tstlold Hldrovfota sgarsdcg i lsmr g,i“fiir uiahetoo t ”oeTm g dfeimh, nd tsbro rihriiB S cotee i ns e nffga d de ecn frimpiatst see n “rrrcuahmtfee osniriiu
naihns glge wi sae”tldha.auinhhvdaliitatid Sn “gwtut etthh, ss wemlrca actitietoe y aooTgasar ot o nbp cohelu esm
dnngditnhpts pnerdd s i rnuuwoto wtiiTti rr ttedmtokd ik fs i ieesfn sona inwc snr g po ir fnsrpmtgcaBncrinltsdddaaesuunds mmsw oo0erlttcneroatih ena o iai eeuh,,dsoooaT e aoecs lttr o oir l iteeuhp uh hutoeeurfdtft ua’soslmtr ghmspiiee ooD onlnm 6 ghimr s epep pzr samribntir.wmsisi t2gc um hybasrtwcep . in- l ndr soea deemnwtsfiidsnauance eeecocshhoriul,cursanioaein ,n lhou reps wdf-m a1ocscaestol e iBrwhacu
roadaarts pr lttt.nifpiaritn,er o umr As A beaeeot toehientnv naoFhp ipfdgo o r n hihr cT-oneeenonruaoMc donehuceFppdtsuirhanrisrit,stisoarln re e udnveeiesaipp gymsot iepc oaFr tipenetot leb.c ffdoorlirt yrxre,tath t noernrncog o mr“cmyredpgintpio ghf rpop eibrudfacog ipnlnn l tas”nebFbolrdj h ouro far t ms wioKinhdhepnpt t aa5ieiJa c eharsmas grgif 5lrecu rgoo p sfeaeekwnl ebhts rdioenKeandl tue rrtMsogdiasspssrtaiza eeednagoityttyt , comnae
Please enable JavaScript to view this content.
lol. News flash; He does given a flying _ _ _ _ about drug prices. Someone told him it would be a good thing to say.
Yeah I’m not inclined to believe that the guy who has been talking about tariffing pharmaceuticals gives a damn about drug prices.
Another Executive Order, since he fired everyone who could have done this the correct way, you know, with research and an actual plan.
Trump promised the same thing last term. Biden got it done. Trump didn’t and probably won’t again.
Seems like we’re overcomplicating the situation.
In exchange for the U.S. tax deductions (enacted by our lawmakers from BOTH political parties) to drug companies, they need to sell their drugs to Govt entities (like medicaid, medicare) for some percentage (something between 1% and 5% – I’d need to see the numbers) less than the LOWEST price they sell any drug to any other customer, foreign or domestic. In other words, Most Favored pricing goes to the U.S. Govt. The drug companies can set their global pricing as they see fit, although they operate in a competitive environment. The only caveat is the U.S. Govt gets Most Favored pricing in exchange for U.S. tax deductions for the drug companies.
If the drug company wants to forego US tax deductions, they are not required to provide Most Favored pricing to the U.S. Govt. Of course, then the U.S. govt can then authorize generic production of any drug.
Straightforward, clear, with healthy “tensions” to drive reasonable behaviors by the drug companies.
LD, I like your plan.
Its Infrastructure Week all over again!
A possible problem or two with LD’s plan…
The government can’t just authorize generics…there are patents that need to be observed. Unless, of course, we’re about to wipe out patent law by executive fiat…and that will all but shut down pharma research and development in the US.
What this does is what we pretty much have already. Pharma is free to sell its product around the world at whatever price. Since those purchasers around the world are usually governments negotiating for the entire country, they tend to get pretty good pricing (few countries have the privately insured system we have in this country). Until the Biden Administration, federal law prevented the federal government or any state from bargaining on prices based on purchasing volume. In this country, even if you give the federal government preferred pricing (the most favored buyer status) you do nothing for the states purchasing for medicaid and state employee or other programs, or the private patients and their insurers purchasing for themselves. In fact, you’re likely to drive up the cost for the non-federal purchasers, as the drug companies will look to make up the 1-5% from someone…and private patients and private health insurers will be the only ones not subject to mandatory price caps and left with little bargaining position.
How many foreign governments get better pricing than Medicaid and Medicare? Would love to see that data. Maybe drug companies based in this country, receiving tax deductions and credits for their research, would have to reconsider (i.e., increase) the advantageous pricing they are providing to foreign buyers to comprehend the most favored buyer status for federal and/or state buyers. Foreign buyers don’t seem to worry as much about U.S. patents – see India).
Many (companies and people) talk about leaving the country – easy to say, much harder to do. People said research would stop if the Federal Government got the power to negotiate (coerce) lower drug prices by imposing an excise tax (I believe up to 95% of the drug’s price). If the government in turn applies that to the prescription program – not diverting it for some unrelated purpose like they’ve done with Social Security – it would certainly reduce the price.
Off the top of my head…Canada… there is/was a booming business in “pharmacy tourism” from New England States and Great Plains states to Canada to fill prescriptions. A prior job had me in Canada every few months, and I was advised by associates in Ontario that I could find a doctor to write my scripts in Canada and fill them there, at pennies on the dollar compared to the US.
Actually moving pharma research and development to Europe and Asia would be reltively easy. Ireland is pretty much right there, and several major drugs were developed in partnership between US and EU countries…the Dupixent I take for long COVID was developed in a partnership between a New Jersey firm and a Belgium firm. Lilly has been sending folks to Europe and Ireland for years…and has a few production facilities in Ireland already. Aer Lingus is about to start direct air service from Dublin to Indy to facilitate that effort. Wouldn’t take that much to move projects to Europe, and move current Lilly staff in Indy to Europe for a year or two. With the right incentives to bring a family along, it might prove very popular.
Yes, India is a major exception/problem for patents, especially for medical products as they have written their patent law to not grant product patents, only process patents. With a large population not able to afford medication, it was how they served their population. I’m not defending it…but that is the reality. But India is an exception, not a the general rule. And its not just US patents, its all medical patents…EU, Asian, US.